Loading…

Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis

Histone deacetylases (HDACs) counterbalance acetylation of lysine residues, a protein modification involved in numerous biological processes. Here, Hdac1 and Hdac2 conditional knock‐out alleles were used to study the function of class I Hdac1 and Hdac2 in cell cycle progression and haematopoietic di...

Full description

Saved in:
Bibliographic Details
Published in:The EMBO journal 2010-08, Vol.29 (15), p.2586-2597
Main Authors: Wilting, Roel H, Yanover, Eva, Heideman, Marinus R, Jacobs, Heinz, Horner, James, van der Torre, Jaco, DePinho, Ronald A, Dannenberg, Jan-Hermen
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Histone deacetylases (HDACs) counterbalance acetylation of lysine residues, a protein modification involved in numerous biological processes. Here, Hdac1 and Hdac2 conditional knock‐out alleles were used to study the function of class I Hdac1 and Hdac2 in cell cycle progression and haematopoietic differentiation. Combined deletion of Hdac1 and Hdac2, or inactivation of their deacetylase activity in primary or oncogenic‐transformed fibroblasts, results in a senescence‐like G 1 cell cycle arrest, accompanied by up‐regulation of the cyclin‐dependent kinase inhibitor p21 Cip . Notably, concomitant genetic inactivation of p53 or p21 Cip indicates that Hdac1 and Hdac2 regulate p53–p21 Cip ‐independent pathways critical for maintaining cell cycle progression. In vivo , we show that Hdac1 and Hdac2 are not essential for liver homeostasis. In contrast, total levels of Hdac1 and Hdac2 in the haematopoietic system are critical for erythrocyte‐megakaryocyte differentiation. Dual inactivation of Hdac1 and Hdac2 results in apoptosis of megakaryocytes and thrombocytopenia. Together, these data indicate that Hdac1 and Hdac2 have overlapping functions in cell cycle regulation and haematopoiesis. In addition, this work provides insights into mechanism‐based toxicities observed in patients treated with HDAC inhibitors.
ISSN:0261-4189
1460-2075
DOI:10.1038/emboj.2010.136